Amantadine in unvaccinated patients with early, mild to moderate COVID‐19: A randomized, placebo‐controlled, double‐blind trial

DOI record: { "DOI": "10.1111/ene.16045", "ISSN": [ "1351-5101", "1468-1331" ], "URL": "http://dx.doi.org/10.1111/ene.16045", "abstract": "<jats:title>Abstract</jats:title><jats:sec><jats:title>Background and purpose</jats:title><jats:p>Adamantanes were listed as an interesting option as an early intervention against COVID‐19. We aimed to evaluate the effectiveness of amantadine in preventing the progression of COVID‐19 and its neurological sequelae.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Unvaccinated patients with confirmed SARS‐CoV‐2 infection within 5 days were enrolled. Subjects were randomized (50:50) to amantadine (AMD; 100 mg twice daily) or placebo (PLB) for 14 days. The Ordinal Scale for Clinical Improvement of the World Health Organization (OSCI‐WHO) was the primary measure. Secondary endpoints included assessment for fatigue; depression, disorders of smell and taste, and sleepiness on Days 1 and 15.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We enrolled 99 patients (49 AMD and 50 PLB). Disease progression (OSCI‐WHO = 4) was observed in 6% (AMD) and 8% (PLB) patients (<jats:italic>p</jats:italic> &gt; 0.05) with further deterioration (OSCI‐WHO〉4) in 0% (AMD) and 8% (PLB) patients (<jats:italic>p</jats:italic> &gt; 0.05). Complete recovery on Day 15 was 60% higher in the AMD compared with the PLB group (<jats:italic>p</jats:italic> = 0.025). There was improvement in taste (AMD: <jats:italic>p</jats:italic> = 0.003; PLB: <jats:italic>p</jats:italic> = 0.0001) and smell (AMD: <jats:italic>p</jats:italic> = 0.005; PLB: <jats:italic>p</jats:italic> = 0.0004) but not in fatigue in both groups. Improvement was observed in the AMD (<jats:italic>p</jats:italic> = 0.010) but not in the PLB group (<jats:italic>p</jats:italic> = 0.058) when assessing depression as well as sleepiness (AMD: <jats:italic>p</jats:italic> = 0.0002; PLB: <jats:italic>p</jats:italic> = 0.341). There was one death in the PLB group (2.0%) and none in the AMD group (<jats:italic>p</jats:italic> &gt; 0.05) until Day 210. Overall, the drug was well tolerated.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>The central effects of amantadine on the nervous system with reduction of sleepiness and depression might have had a supportive effect on faster recovery in early COVID‐19 patients.</jats:p></jats:sec>", "alternative-id": [ "10.1111/ene.16045" ], "assertion": [ { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Received", "name": "received", "order": 0, "value": "2023-06-26" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Accepted", "name": "accepted", "order": 1, "value": "2023-08-08" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Published", "name": "published", "order": 2, "value": "2023-09-14" } ], "author": [ { "ORCID": "http://orcid.org/0000-0002-7019-6681", "affiliation": [ { "name": "Department of Neurology Medical University of Lublin Lublin Poland" } ], "authenticated-orcid": false, "family": "Rejdak", "given": "Konrad", "sequence": "first" }, { "affiliation": [ { "name": "Department of General and Transplantation Surgery Medical University of Warsaw Warsaw Poland" } ], "family": "Fiedor", "given": "Piotr", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Neurology and Clinical Neuroimmunology Regional Specialist Hospital Grudziadz Poland" } ], "family": "Bonek", "given": "Robert", "sequence": "additional" }, { "affiliation": [ { "name": "Regional Hospital SPZZOZ in Wyszkόw Wyszkόw Poland" } ], "family": "Łukasiak", "given": "Jacek", "sequence": "additional" }, { "affiliation": [ { "name": "Regional Hospital SPZZOZ in Wyszkόw Wyszkόw Poland" } ], "family": "Chełstowski", "given": "Waldemar", "sequence": "additional" }, { "affiliation": [ { "name": "Independent Voivodeship Hospital “Jana Bożego” in Lublin Lublin Poland" } ], "family": "Kiciak", "given": "Sławomir", "sequence": "additional" }, { "affiliation": [ { "name": "Independent Voivodeship Hospital “Jana Bożego” in Lublin Lublin Poland" } ], "family": "Dąbrowski", "given": "Piotr", "sequence": "additional" }, { "affiliation": [ { "name": "Collegium Medicum University of Rzeszów and St. Queen Jadwiga Clinical District Hospital No. 2 Rzeszów Poland" } ], "family": "Gala‐Błądzińska", "given": "Agnieszka", "sequence": "additional" }, { "affiliation": [ { "name": "SPZOZ Kalwaria Zebrzydowska Kalwaria Zebrzydowska Poland" } ], "family": "Dec", "given": "Mateusz", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Neurology Medical University of Lublin Lublin Poland" } ], "family": "Papuć", "given": "Ewa", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Neurology Medical University of Lublin Lublin Poland" } ], "family": "Zasybska", "given": "Adriana", "sequence": "additional" }, { "affiliation": [ { "name": "Jagiellonian University Medical College Kraków Poland" } ], "family": "Kaczor", "given": "Marcin", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Experimental Pharmacology Mossakowski Medical Research Institute, Polish Academy of Sciences Warsaw Poland" } ], "family": "Grieb", "given": "Paweł", "sequence": "additional" }, { "affiliation": [], "name": "COV‐PREVENT Study Group", "sequence": "additional" } ], "container-title": "European Journal of Neurology", "container-title-short": "Euro J of Neurology", "content-domain": { "crossmark-restriction": true, "domain": [ "onlinelibrary.wiley.com" ] }, "created": { "date-parts": [ [ 2023, 8, 16 ] ], "date-time": "2023-08-16T16:08:18Z", "timestamp": 1692202098000 }, "deposited": { "date-parts": [ [ 2024, 1, 22 ] ], "date-time": "2024-01-22T06:39:13Z", "timestamp": 1705905553000 }, "funder": [ { "DOI": "10.13039/501100023181", "doi-asserted-by": "publisher", "name": "Agencja Badań Medycznych" } ], "indexed": { "date-parts": [ [ 2024, 1, 22 ] ], "date-time": "2024-01-22T07:10:19Z", "timestamp": 1705907419620 }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2023, 9, 14 ] ] }, "journal-issue": { "issue": "1", "published-print": { "date-parts": [ [ 2024, 1 ] ] } }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 9, 14 ] ], "date-time": "2023-09-14T00:00:00Z", "timestamp": 1694649600000 } } ], "link": [ { "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.16045", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "311", "original-title": [], "prefix": "10.1111", "published": { "date-parts": [ [ 2023, 9, 14 ] ] }, "published-online": { "date-parts": [ [ 2023, 9, 14 ] ] }, "published-print": { "date-parts": [ [ 2024, 1 ] ] }, "publisher": "Wiley", "reference": [ { "DOI": "10.1016/S1473-3099(20)30484-9", "doi-asserted-by": "publisher", "key": "e_1_2_11_2_1" }, { "DOI": "10.1002/jmv.26030", "doi-asserted-by": "publisher", "key": "e_1_2_11_3_1" }, { "article-title": "What can Parkinson's disease teach us about COVID‐19?", "author": "Tipton PW", "first-page": "204", "journal-title": "Neurol Neurochir Pol", "key": "e_1_2_11_4_1", "volume": "54", "year": "2020" }, { "DOI": "10.1016/S1474-4422(19)30361-8", "doi-asserted-by": "publisher", "key": "e_1_2_11_5_1" }, { "DOI": "10.1007/s00702-021-02306-2", "doi-asserted-by": "publisher", "key": "e_1_2_11_6_1" }, { "DOI": "10.1016/S1474-4422(21)00356-2", "doi-asserted-by": "publisher", "key": "e_1_2_11_7_1" }, { "DOI": "10.1016/j.msard.2020.102163", "doi-asserted-by": "publisher", "key": "e_1_2_11_8_1" }, { "DOI": "10.5114/fn.2021.107572", "doi-asserted-by": "publisher", "key": "e_1_2_11_9_1" }, { "DOI": "10.1016/j.crphar.2021.100030", "doi-asserted-by": "publisher", "key": "e_1_2_11_10_1" }, { "DOI": "10.1016/j.ijantimicag.2020.106004", "doi-asserted-by": "publisher", "key": "e_1_2_11_11_1" }, { "DOI": "10.1038/s42003-021-02866-9", "doi-asserted-by": "publisher", "key": "e_1_2_11_12_1" }, { "DOI": "10.3390/v13040539", "doi-asserted-by": "publisher", "key": "e_1_2_11_13_1" }, { "article-title": "All‐cause mortality among patients treated with repurposed antivirals and antibiotics for COVID‐19 in Mexico City: a real‐world observational study", "author": "Mancilla‐Galindo J", "first-page": "199", "journal-title": "EXCLI J", "key": "e_1_2_11_14_1", "volume": "20", "year": "2021" }, { "DOI": "10.1007/s43440-020-00168-1", "doi-asserted-by": "publisher", "key": "e_1_2_11_15_1" }, { "DOI": "10.3389/fneur.2021.704186", "doi-asserted-by": "publisher", "key": "e_1_2_11_16_1" }, { "DOI": "10.1016/j.rmed.2023.107198", "doi-asserted-by": "publisher", "key": "e_1_2_11_17_1" }, { "DOI": "10.1016/j.ijid.2022.09.026", "doi-asserted-by": "publisher", "key": "e_1_2_11_18_1" }, { "DOI": "10.1016/j.cct.2022.106755", "doi-asserted-by": "publisher", "key": "e_1_2_11_19_1" }, { "key": "e_1_2_11_20_1", "unstructured": "World Health Organization.WHO R&D Blueprint. Novel coronavirus. COVID‐19 therapeutic trial synopsis.https://www.who.int/docs/default‐source/blue‐print/covid‐19‐therapeutic‐trial‐synopsis.pdf" }, { "DOI": "10.1001/archneur.1989.00520460115022", "doi-asserted-by": "publisher", "key": "e_1_2_11_21_1" }, { "DOI": "10.1001/archpsyc.1961.01710120031004", "doi-asserted-by": "publisher", "key": "e_1_2_11_22_1" }, { "DOI": "10.1017/S002221511200076X", "doi-asserted-by": "publisher", "key": "e_1_2_11_23_1" }, { "DOI": "10.1093/sleep/14.6.540", "doi-asserted-by": "publisher", "key": "e_1_2_11_24_1" }, { "DOI": "10.7326/0003-4819-85-2-177", "doi-asserted-by": "publisher", "key": "e_1_2_11_25_1" }, { "DOI": "10.1086/508665", "doi-asserted-by": "publisher", "key": "e_1_2_11_26_1" }, { "DOI": "10.1016/S0140-6736(98)05805-X", "doi-asserted-by": "publisher", "key": "e_1_2_11_27_1" }, { "DOI": "10.1016/j.cmi.2023.06.023", "doi-asserted-by": "publisher", "key": "e_1_2_11_28_1" }, { "DOI": "10.1016/j.ccc.2022.03.002", "doi-asserted-by": "publisher", "key": "e_1_2_11_29_1" }, { "DOI": "10.1016/S2215-0366(22)00260-7", "doi-asserted-by": "publisher", "key": "e_1_2_11_30_1" }, { "DOI": "10.1007/s40268-021-00351-6", "doi-asserted-by": "publisher", "key": "e_1_2_11_31_1" }, { "DOI": "10.1080/17512433.2023.2176301", "doi-asserted-by": "publisher", "key": "e_1_2_11_32_1" } ], "reference-count": 31, "references-count": 31, "relation": {}, "resource": { "primary": { "URL": "https://onlinelibrary.wiley.com/doi/10.1111/ene.16045" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Neurology (clinical)", "Neurology" ], "subtitle": [], "title": "Amantadine in unvaccinated patients with early, mild to moderate <scp>COVID</scp>‐19: A randomized, placebo‐controlled, double‐blind trial", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1002/crossmark_policy", "volume": "31" }